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Background: Aberrant glycosylation is a hallmark of cancer cells and plays an important role in
oncogenesis and cancer progression including metastasis. This study aimed to assess alteration in cellular
glycosylation, detected by lectin Helix pomatia agglutinin (HPA) binding, in adrenal cancers and to
determine whether such altered glycosylation has prognostic significance.
Methods: HPA binding lectin histochemistry was performed on archival paraffin wax-embedded spec-
imens of adrenocortical cancers excised from patients attending two tertiary referral centres. Benign
tumours were used as controls. Demographic, histological and survival data were collected and compared
between patients with HPA-positive and HPA-negative tumours.
Results: Thirty-two patients were treated for adrenal cancer between 2000 and 2016; their median age
was 49 (range 23–79) years. Fifteen patients had functioning tumours (14 adrenal Cushing’s tumours and
1 Conn’s tumour). Mean(s.d.) tumour size was 127⋅71(49⋅70) mm. None of 10 control tumours expressed
HPA-binding glycoproteins. Invasion was associated with HPA-binding glycoproteins (P= 0⋅018). Local
recurrence or metastatic disease did not significantly differ between HPA-positive and HPA-negative
adrenocortical cancers. Overall survival was significantly longer in patients with HPA-negative tumours
(median survival not reached versus 22months in patients with HPA-positive tumours; P= 0⋅002).
Conclusion: Altered cellular glycosylation detected by lectin HPA is associated with poor survival in
patients with adrenocortical cancer.
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Introduction
Adrenocortical cancers are rare endocrine tumours with
an incidence of about 1–2 per million population. This
disease appears to have a higher prevalence in women and
is associated with extremely poor prognosis1–5. Factors
that predict prognosis include stage of the disease and
complete resection (R0) of the tumour6.Molecularmarkers
of prognosis include Ki-67 proliferation index above 10 per
cent7, high steroidogenic factor 1 expression8, mutation of
tumour suppressor gene TP53, and loss of retinoblastoma
protein expression9.
Cell surface glycoproteins play an important role in cell
recognition, signalling, proliferation and differentiation10.
There are two main types of protein glycosylation:
N-linked (a N-acetylglucosamine (GlcNAc) residue is
added to the Asn residue within a consensus peptide
sequence of Asn–X–Ser/Thr, where X can be any amino
acid except proline) andO-linked (aN-acetylgalactosamine
(GalNAc) residue is added to the hydroxyl group of Ser or
Thr residue on the polypeptide) glycosylation.
Alteration in glycosylation is associated with invasive
and metastatic potential in some cancer types11. Binding
of the lectin Helix pomatia agglutinin (HPA) has been
reported as a marker of altered O-glycosylation in cancer.
This has been shown in a wide range of human cancers
including lung, breast, prostate, stomach, thyroid and col-
orectal cancer12–18. HPA recognizes a range of O-linked
glycans bearing the terminal monosaccharide GalNAc19,
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including blood group A substance, Forssman antigens20,
Tn epitope21 and, to a lesser extent, terminal GlcNAc22.
Studies on aberrant glycosylation in adrenocortical cancer
have not been reported.
The aims of this study were to assess alteration in cellular
glycosylation, detected by HPA binding in adrenal cancers,
and to determine whether such altered glycosylation has
prognostic significance.
Methods
Patient selection and follow-up procedure
This was a retrospective study of patients who underwent
surgery for adrenocortical cancer at two tertiary referral
centres (Singapore and Oxford) between January 2000 and
December 2016. Patients were eligible if archival paraf-
fin wax-embedded specimens were available and they had
been followed up. Lectin histochemistry was performed to
detect binding of HPA. All patients were followed until
death or to the end ofDecember 2016. Ethical approval was
obtained from the institutional boards (IRB: 2014/00378;
REC: 11/SC/0396).
Preoperative investigation
All patients underwent two 24-h urine biochemical eval-
uations to exclude the diagnosis of phaeochromocytoma
bymeasuring 24-h urinarymetadrenalines, excessive secre-
tion of steroids and their precursors, aldosterone and
cortisol, to differentiate non-functional from functional
tumours. CTof the chest and abdomenwas performedwith
contrast injection to assess characteristics of the tumour,
lymph node involvement, adjacent organ invasion (of kid-
ney, distal pancreas, spleen, liver or diaphragm), pres-
ence of intravascular thrombus in the inferior vena cava
(IVC) or renal vein, and metastasis. If intravascular throm-
bus was suspected, further evaluation was performed with
MRI. [18F]fluorodeoxyglucose PET was performed annu-
ally as part of follow-up surveillance to detect metastasis
or if patients had progression of symptoms. Both institu-
tions followed similar protocols in terms of biochemical
assessments and radiological investigations. In later years,
however, PET was used more frequently for staging and
assessment for metastasis.
Demographic data
Demographic data, histological data, recurrence of dis-
ease, local invasion and mortality data were collected.
Survival was estimated as overall survival (OS), defined
as duration of survival from the date of surgery to the
date of last follow-up, and recurrence-free survival (RFS),
defined as the interval between surgery and diagnosis
of recurrence for relapsed patients or from the date of
surgery to date of last follow-up for patients without
recurrence.
Lectin histochemistry
Lectin immunohistochemistry was performed on 5-μm
thick paraffin wax-embedded clinical adrenal tumour sam-
ples using an avidin–biotin labelling technique validated by
Brooks and Wilkinson23 to reveal binding of lectin HPA.
For positive controls, sections of rat kidney, which shows
strong and characteristic HPA labelling, were included in
each labelling experiment. For negative controls, the lectin
was omitted and the specificity of binding was confirmed
by incubating the sections with HPA in the presence of
0⋅1-mol/l GalNAc. Ten benign adrenal tumours were also
assessed for controls.
Paraffin wax sections were dewaxed in xylene and rehy-
drated through a series of graded alcohols (100, 90 and
70 per cent (v/v)) to water. Endogenous peroxidases were
then quenched by soaking the sections in 3 per cent (v/v)
hydrogen peroxide in methanol for 20min at room tem-
perature before washing gently in running tap water for
5min. The sections were then trypsinized in 0⋅1 per cent
(w/v) trypsin (crude type II from porcine pancreas) and
0⋅1 per cent (w/v) calcium chloride in lectin buffer (0⋅6 per
cent (w/v) Tris, 0⋅085 per cent (w/v) sodium chloride, 0⋅02
per cent (w/v) magnesium chloride, 0⋅01 per cent calcium
chloride, pH 7⋅6) at 37oC for 20min, in order to reveal
lectin-binding sites. The slides were washed in gently run-
ning tap water for 5min after the trypsinization procedure.
Biotinylated HPA was diluted in blocking buffer (5 per
cent (w/v) bovine serum albumin in lectin buffer) at a con-
centration of 10 μg/ml. The slides were incubated with this
solution for 1 h, washed in several changes of lectin buffer,
and then incubated with 5-μg/ml horseradish peroxidase
conjugated avidin for 30min. The sections were washed
again in several changes of lectin buffer, and then lectin
binding was revealed by incubation with hydrogen peroxi-
dase/diaminobenzidine (DAB) (DAB Perioxidase Substrate
Kit; Vector Laboratories, Burlingame, California, USA),
prepared according to manufacturer’s instructions, for
10min. The sections were washed for 5min under run-
ning tap water and then lightly counterstained in Mayer’s
haematoxylin. After blueing under running tap water,
the sections were dehydrated through a series of graded
alcohols (70 per cent (v/v), 90 per cent (v/v), 100 per
cent), cleared in xylene, and mounted in DPX resinous
mountant.
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Assessment of Helix pomatia agglutinin labelling
The guidelines described by Brooks and colleagues24 were
used to classify the labelling of sections as positive or neg-
ative for HPA binding. Sections were scored as positive
when 5 per cent or more of the cancer cells labelled posi-
tively for HPA binding and as negative when less than 5 per
cent labelled positively. Assessments of HPA binding were
performed by two observers who were blinded to the iden-
tity of the sample, and their results were compared. In cases
of discordance, consensus was obtained after discussion.
Interobserver variability was calculated by κ index using
the formula: K=Po−Pe/1−Pe, where Po is observed pro-
portionate agreement and Pe is overall random agreement
probability.
Statistical analysis
Statistical analyses were performed with SPSS®
version 22.0 (IBM, Armonk, New York, USA). The
association between positive HPA labelling and clinico-
pathological variables was analysed using the χ2 test and
Wilcoxon signed rank test. Survival curves were deter-
mined by Kaplan–Meier analysis and compared with
the log rank test. P< 0⋅050 was considered statistically
significant.
Results
Patient and tumour characteristics
Forty-seven patients were eligible for this study; 15 were
excluded because they had no follow-up (2) or tissue blocks
were not available (13). Of the 32 included patients, 21 and
11 were operated on in Oxford and Singapore respectively;
their demographic profile is shown in Table 1. Fifteen of
the 32 tumours were functional and malignant (showed
features of capsular and vascular invasion, extra-adrenal
extension, high mitotic figures, tumour necrosis and
large size).
Treatment modalities for the patients were: surgery
in 30 and adjuvant mitotane in 22. Four patients who
received mitotane also underwent salvage chemotherapy
with doxorubicin, cisplatin and doxorubicin. In patients
who had surgery, 13 underwent adrenalectomy only and
17 had en bloc resection with nephrectomy (10), splenec-
tomy (9), pancreatectomy (5) and IVC thrombectomy
(4). Two patients did not undergo surgery and diagnosis
was confirmed by CT-guided biopsy. In 13 patients who
underwent adrenalectomy only, malignancy was suspected
in five cases but there were no features of local invasion on
imaging warranting contiguous organ resection.
Table 1 Demographics of the study population
No. of patients
(n= 32)*
Age (years)† 49 (23–79)
Sex ratio (M : F) 15 : 17
Diagnosis
Non-functioning tumour 17
Cushing’s tumour 14
Conn’s tumour 1
Tumour size (mm)‡ 127⋅71(49⋅70)
Tumour stage
I 5
II 5
III 5
IV 17
Treatment
Biopsy only 2
Adrenalectomy 13
Adrenalectomy + en bloc resection 17
Adjuvant treatment
Mitotane only 22
Mitotane + other chemotherapy 4
Radiotherapy 2
Local invasion
Yes 26
No 6
Metastasis
Yes 14
No 18
Died 21
*Unless indicated otherwise, values are †median (range) and ‡mean(s.d.).
Based on the AJCC criteria, 17 patients had stage IV
disease, and local invasion was observed in 26 patients.
Fourteen of the 32 patients developed metastases, predom-
inantly pulmonary. The next most common site of metas-
tasis was the liver, followed by bone.
Median OS was 30 (range 1–168) months, RFS was 30
(6–156) months. The mortality rate for the cohort was
66 per cent (21 of 32) over the study period. Five of the
13 patients who had adrenalectomy alone developed local
recurrence, and six of 17 had local recurrence following a
radical en bloc resection.
Helix pomatia agglutinin labelling of tissue samples
Positive labelling for HPA binding was observed in 19
of the 32 patients. The difference in labelling between
positive and negative tumours is shown in Fig. 1. Labelling
was not observed in negative controls where HPA was
omitted, or where HPA incubation took place in the
presence of inhibiting GalNAc. The κ index between
observers was 0⋅75, indicating satisfactory inter-rater
reliability for the immunohistochemical assessment of
tumour samples.
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a  Positive HPA labelling b  Membrane and cytoplasmic staining
d  Absent membrane and cytoplasmic stainingc  Negative HPA labelling
e  Staining of normal adrenal gland
Fig. 1 Results ofHelix pomatia agglutinin (HPA) lectin immunohistochemistry in the tumours studied: a positive HPA labelling, as shown
by intense deep brown staining, in adrenocortical cancer (ACC) (magnification ×10); b intense membrane and cytoplasmic staining of
cancer cells (magnification ×20); c negative HPA binding in ACC with absence of any labelling (magnification ×10); d absent membrane
and cytoplasmic staining of cancer cells (magnification ×20); e absent staining with HPA in a normal adrenal gland (magnification ×10)
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Table 2 Correlation between Helix pomatia agglutinin binding
and clinicopathological variables
Positive
HPA binding
(n= 19)
Negative
HPA binding
(n= 13) P*
Sex ratio (M : F) 10 : 9 5 : 8 0⋅430
Tumour type 0⋅273
Cushing’s tumour 10 4
Conn’s tumour 1 –
Non-functioning tumour 8 9
Type of surgery 0⋅524
Biopsy only 1 1
Adrenalectomy 8 5
En bloc resection 10 7
Tumour stage 0⋅451
I 4 1
II 2 3
III 2 3
IV 11 6
Invasion 0⋅018
Yes 18 8
No 1 5
Recurrence 0⋅961
Yes 6 4
No 13 9
Metastasis 0⋅618
Yes 9 5
No 10 8
Mitotane therapy 0⋅467
Yes 14 8
No 5 5
Weiss score 0⋅945
≥ 3 9 6
< 3 10 7
Died 0⋅007
Yes 16 5
No 3 8
HPA, Helix pomatia agglutinin. *Log rank test.
Correlation between clinicopathological variables
The correlation between the various clinicopathological
variables and HPA labelling is shown in Table 2. No signif-
icant correlation was observed between HPA labelling and
sex, histological diagnosis, tumour recurrence, stage of the
disease, presence or absence of metastasis and adjuvant
therapy. Of the 26 patients with features of local invasion,
18 had positive HPA labelling and eight negative HPA
labelling (P= 0⋅018). Similarly, positive HPA labelling was
seen in six of the ten patients with tumour recurrence
(P= 0⋅961).
Significance of positive Helix pomatia agglutinin
labelling
In univariable analysis, sex, type of surgery, stage, recur-
rence, metastasis, Weiss score and adjuvant therapy did
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Fig. 2 Kaplan–Meier survival curves for patients with positive
and negative Helix pomatia agglutinin (HPA) immunolabelling.
P= 0⋅002 (log rank test)
not influence survival. Local invasion (P= 0⋅018) and posi-
tive HPA labelling (P= 0⋅007) were significantly correlated
with survival (Table 2).
Differences in survival between patients with tumours
that were positive or negative for HPA labelling are
shown in Fig. 2. Patients with positive HPA labelling had
a median survival of 22 (range 2–156) months; at the
end of follow-up, 16 of 19 had died. Of patients with
negative HPA binding, all but three were alive at the end
of the analysis period, with a mortality rate of 23 per cent
(3 of 13); their survival was significantly better than that in
patients with positive HPA labelling (P= 0⋅002).
Discussion
This study has shown that aberrant glycosylation
detectable by HPA lectin histochemistry is a predictor
of poor survival in adrenal cancer. Glycosylation is the
most common post-translational modification of proteins
and plays an important role in cell communication, interac-
tion and adhesion25. Aberrant glycosylation is more likely
to be seen in tumours with a more aggressive phenotype26.
In the present study, lectin cells showed significant cell
membrane localization ofHPA-binding glycans where pos-
itive. The results were similar to those shown by Peiris and
colleagues18 in metastatic colorectal cancer. The labelling
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pattern appeared to show an all-or-nothing effect: the can-
cers either labelled as clearly positive or completely neg-
ative. This is similar to the labelling pattern described by
Brooks and Wilkinson in breast cancer23.
Adrenocortical carcinoma is an aggressive cancer with
5-year survival rates of up to 60 per cent, with surgery
the only effective curative treatment. Factors that affect
survival include patient age, stage, completeness of resec-
tion, local invasion, functionality and metastasis27. In the
present study there was no relationship betweenHPA lectin
labelling and parameters including age, sex, histological
type, surgery and chemotherapy. Positive HPA labelling
was, however, associated with an increased risk of local
invasion and significantly decreased median survival. Pos-
itive HPA labelling was not correlated with metastasis,
unlike findings in studies of breast and colonic cancer18,28.
In studies that showed a correlation with metastatic state,
the two main binding partners of HPA were identified as
integrin α5 and α6, and annexin 2 and 418,29. These two
binding partners were not evaluated in the present study.
The exact binding partners in adrenal cancer are yet to be
identified; characterization using affinity chromatography
and mass spectrometry is required.
Markers such as Ki-67 labelling index have been used
to determine prognosis in adrenal cancer7,30,31 but con-
tinue to have significant variability in reporting amongst
pathologists32. A recent publication32 on reporting vari-
ability described Ki-67 as an unreliable marker. In the
present cohort, any association betweenKi-67 and progno-
sis was not analysed as data pertaining to this variable were
missing for several patients. HPA labelling was, in contrast,
straightforward to interpret as positive or negative, mak-
ing HPA lectin labelling a promising marker of prognosis
in adrenal cancer.
Some studies33,34 have shown that cortisol-secreting
adrenocortical cancers are associated with a poor progno-
sis. There was no difference in HPA binding or survival
between functioning and non-functioning adrenocortical
cancers in the present cohort. It has been reported35,36 that
patients who received treatment with mitotane immedi-
ately after surgery had improved survival compared with
those treated later after surgery, but another study37 did
not show such a difference. The present study did not
show a statistically significant difference in survival and
HPA binding between patients who received mitotane and
those who did not.
The limitations of this study include the small sample size
with its inherent biases, the loss of 15 patients who could
not be included in the study, and the retrospective design.
Positive HPA lectin labelling has the potential to
be used as a marker of poor prognosis in patients
with adrenocortical cancers, along with other currently
used markers.
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